GlaxoSmithKline has signed an agreement with Dr. Reddy’s to develop and market selected products across an extensive number of emerging markets, excluding India.
Under the terms of the agreement, GSK will gain exclusive access to Dr. Reddy’s diverse portfolio and future pipeline of more than 100 branded pharmaceuticals. These products and pipeline falls under the fast growing therapeutic segments such as cardiovascular, diabetes, oncology, gastroenterology and pain management.
The products will be manufactured by Dr. Reddy’s and licensed and supplied by GSK in various countries in Africa, the Middle East, Asia Pacific and Latin America. In certain markets, products will be co-marketed by GSK and Dr. Reddy’s. Under the terms of the agreement, revenues will be reported by GSK and shared with Dr. Reddy’s as per the agreed terms.
Abbas Hussain, President, Emerging Markets at GlaxoSmithKline, said: “This is another significant step forward in our strategy to grow and diversify GSK’s business in emerging markets. Growth in both population and economic prosperity is leading to increased demand for branded pharmaceuticals. This new alliance will combine Dr. Reddy’s portfolio of quality branded pharmaceuticals together with GSK’s extensive sales and marketing capabilities. Together we will be able to deliver more medicines of value to more patients in these countries.”